Insulet Cuts 2026 Guidance Amid Execution Pressures, Eyes Strong Long-Term Growth

Insulet Corporation, a developer of automated insulin delivery systems, presented its outlook at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, revising its 2026 constant-currency growth forecast down to a range of 12% to 17% from prior expectations. The company’s stock has fallen nearly 60% over the past year, trading around $131.96 as of the latest data, though it remains below its 52-week high of $354.88. Despite the short-term downturn, Insulet emphasized execution challenges as the primary driver for the adjustment, citing urgency in addressing operational hurdles rather than structural market limitations. The company also raised its adjusted earnings-per-share (EPS) growth target to better than 30% annually, reflecting confidence in its long-term profitability trajectory. With a gross profit margin of 71% over the past year, Insulet aims to maintain an annual operating margin expansion target of 100 basis points, underscoring disciplined cost management amid growth pressures. Analysts have revised earnings expectations downward for the upcoming period, though the company’s valuation metrics—including a P/E ratio of 26.4 and a PEG ratio of 0.44—remain relatively attractive for investors seeking exposure to the diabetes care sector. The company’s focus remains firmly on its core product suite, including its Omnipod system, which has seen strong adoption in international markets, with 75% of its installed base converting from its DASH platform to Omnipod 5. Insulet’s international growth outlook has been elevated, with 2024 expansion targets now set at 30% to 32%, driven by strategic expansions in Spain, Germany, Canada, Saudi Arabia, and the Middle East. The company’s pipeline remains robust, with key milestones including the second algorithm enhancement for Libre 3 Plus in 2024, expanding access to over 450,000 patients primarily using multiple daily injections (MDI). Omnipod 6, slated for 2025, is expected to feature a third algorithm improvement, an enhanced antenna design, and broader wear flexibility, while a fully closed-loop type 2 diabetes system—currently in pivotal clinical trials—is targeted for commercialization in 2027. This system is projected to deliver clinically meaningful improvements, including a 12-point increase in time in range, a 30% reduction in insulin use, and zero manual bolusing, setting a new benchmark for automated diabetes management. The company’s clinical data for the closed-loop system has shown promising results, including A1C reductions and weight maintenance, while home training time is reported to be under 40 minutes. Insulet’s manufacturing capacity is expanding, with a fourth plant under construction to support tens of millions of units annually. The company has also addressed quality concerns with two Class I Medical Device Corrections issued in 2024, with root-cause analyses complete and no fatalities reported. The diabetes market remains vast, with type 2 diabetes representing a $28 billion total addressable market, though penetration of automated insulin delivery systems remains low. Around 2.5 million people use basal bolus insulin, with automated insulin delivery (AID) penetration at just 5% and continuous glucose monitoring (CGM) penetration well north of 50% in the basal-only population. Two-thirds of insulin-treated type 2 diabetes patients are not meeting glycemic goals, presenting significant unmet need. Insulet’s leadership, including President and CEO Ashley McEvoy and Executive Vice President Flavia Pease, emphasized the company’s strategic focus on international expansion and innovation as key drivers of long-term growth, despite recent execution challenges.